Jackson Square Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Jackson Square Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$735K	Hold	63,773	–	–	0.11%	88
2026 Q2	$953K	Hold	63,773	–	–	0.13%	76
2026 Q1	$933K	Hold	63,773	–	–	0.2%	70
2025 Q4	$491K	Hold	63,773	–	–	0.1%	108
2025 Q3	$470K	Hold	63,773	–	–	0.1%	107
2025 Q2	$255K	Hold	63,773	–	–	0.06%	136
2025 Q1	$203K	Hold	63,773	–	–	0.07%	131
2024 Q4	$341K	Hold	63,773	–	–	0.08%	128
2024 Q3	$337K	Hold	63,773	–	–	0.08%	116
2024 Q2	$116K	Hold	63,773	–	–	0.03%	126
2024 Q1	$114K	Hold	63,773	–	–	0.03%	135
2023 Q4	$112K	Hold	63,773	–	–	0.04%	116
2023 Q3	$93.1K	Hold	63,773	–	–	0.04%	107
2023 Q2	$146K	Hold	63,773	–	–	0.06%	111
2023 Q1	$58K	Hold	63,773	–	–	0.03%	106
2022 Q4	$54.2K	Hold	63,773	–	–	0.03%	118
2022 Q3	$52K	Hold	63,773	–	–	0.03%	120
2022 Q2	$63K	Hold	63,773	–	–	0.03%	137
2022 Q1	$105K	Buy	+63,773	New	+$117K	0.03%	177

Other funds holding CRVS

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Avity Investment Management Greenwich, Connecticut $1.6B AUM 32.15% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Western Pacific Wealth Management Lake Forest, Illinois $119M AUM 20.8% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Jackson Square Capital's CRVS Position: Q3 2026 in Review

Jackson Square Capital held its Corvus Pharmaceuticals (CRVS) position steady in Q3 2026 at 63,773 shares worth $735K. The position accounts for 0.11% of the portfolio, ranked #88.

Jackson Square Capital first reported a position in CRVS in Q1 2022 and has held it in 19 quarters since. The position peaked at $953K in Q2 2026. 16 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

Jackson Square Capital held 63,773 shares of Corvus Pharmaceuticals worth $735K as of Q3 2026.
Jackson Square Capital left its Corvus Pharmaceuticals share count unchanged in Q3 2026.
Corvus Pharmaceuticals made up 0.11% of Jackson Square Capital's portfolio in Q3 2026, its #88 holding.
Jackson Square Capital first reported a position in Corvus Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
Jackson Square Capital's Corvus Pharmaceuticals position peaked at $953K in Q2 2026.
16 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Jackson Square Capital's 13F filing for Q3 2026, filed 19 Oct 2026.